Pertussis in adults: epidemiology, signs, symptoms, and implications for vaccination - PubMed (original) (raw)
Review
. 1999 Jun:28 Suppl 2:S147-50.
doi: 10.1086/515061.
Affiliations
- PMID: 10447034
- DOI: 10.1086/515061
Review
Pertussis in adults: epidemiology, signs, symptoms, and implications for vaccination
W A Orenstein. Clin Infect Dis. 1999 Jun.
Abstract
Transmission of pertussis among adults is being increasingly recognized. About 1 or 2 in 1,000 adolescents and adults develop pertussis each year, > or = 12% of persons with acute cough illnesses of at least 1-2 weeks' duration have evidence of pertussis infection, and adults have been the source of pertussis for younger children. The advent of acellular pertussis vaccines, if safe and effective in adults, offers the opportunity to prevent transmission of pertussis in older populations. Several issues should be clarified before routine immunization is recommended, including the health burden of pertussis in adults and adolescents to be prevented by vaccination and how much morbidity resulting from pertussis in infants and children would be indirectly prevented. Preliminary studies suggest that pertussis vaccines are safe and immunogenic in adults. Potential recommendations for future vaccination might include all adolescents and adults at 10-year intervals along with the adult tetanus-diphtheria toxoids booster. Cost-benefit or cost-effectiveness analyses would be useful in developing vaccination policies for adults.
Similar articles
- Pertussis in adolescents and adults: should we vaccinate?
Lee GM, Lebaron C, Murphy TV, Lett S, Schauer S, Lieu TA. Lee GM, et al. Pediatrics. 2005 Jun;115(6):1675-84. doi: 10.1542/peds.2004-2509. Pediatrics. 2005. PMID: 15930232 - Adolescent and adult pertussis: disease burden and prevention.
Edwards K, Freeman DM. Edwards K, et al. Curr Opin Pediatr. 2006 Feb;18(1):77-80. doi: 10.1097/01.mop.0000192520.48411.fa. Curr Opin Pediatr. 2006. PMID: 16470167 Review. - Indications for acellular pertussis vaccines in adults: the case for selective, rather than universal, recommendations.
Gardner P. Gardner P. Clin Infect Dis. 1999 Jun;28 Suppl 2:S131-5. doi: 10.1086/515059. Clin Infect Dis. 1999. PMID: 10447031 - Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
America Academy of Pediatrics Commitee on Infectious Diseases. America Academy of Pediatrics Commitee on Infectious Diseases. Pediatrics. 2006 Mar;117(3):965-78. doi: 10.1542/peds.2005-3038. Epub 2005 Dec 28. Pediatrics. 2006. PMID: 16382131 - Boostrix: a reduced-dose acellular pertussis vaccine for use in adolescents and adults.
Li WC, Wu TZ, Huang YC, Huang LM. Li WC, et al. Expert Rev Vaccines. 2009 Oct;8(10):1317-27. doi: 10.1586/erv.09.96. Expert Rev Vaccines. 2009. PMID: 19803753 Review.
Cited by
- Reduced-antigen combined diphtheria-tetanus-acellular pertussis vaccine (Boostrix).
Chapman TM, Goa KL. Chapman TM, et al. Drugs. 2003;63(13):1407-13; discussion: 1415-6. doi: 10.2165/00003495-200363130-00005. Drugs. 2003. PMID: 12825963 Review. - Cost-effectiveness of adolescent pertussis vaccination for the Netherlands: using an individual-based dynamic model.
de Vries R, Kretzschmar M, Schellekens JF, Versteegh FG, Westra TA, Roord JJ, Postma MJ. de Vries R, et al. PLoS One. 2010 Oct 15;5(10):e13392. doi: 10.1371/journal.pone.0013392. PLoS One. 2010. PMID: 20976213 Free PMC article. - Economic evaluation of an extended acellular pertussis vaccine program for adolescents in Québec, Canada.
Iskedjian M, Walker JH, De Serres G, Einarson TR. Iskedjian M, et al. Paediatr Drugs. 2005;7(2):123-36. doi: 10.2165/00148581-200507020-00005. Paediatr Drugs. 2005. PMID: 15871632 - Rapid and Accurate Diagnosis of the Respiratory Disease Pertussis on a Point-of-Care Biochip.
Dou M, Macias N, Shen F, Bard JD, Domínguez DC, Li X. Dou M, et al. EClinicalMedicine. 2019 Feb;8:72-77. doi: 10.1016/j.eclinm.2019.02.008. Epub 2019 Mar 5. EClinicalMedicine. 2019. PMID: 31008450 Free PMC article. - Emerging Infections and Pertinent Infections Related to Travel for Patients with Primary Immunodeficiencies.
Sullivan KE, Bassiri H, Bousfiha AA, Costa-Carvalho BT, Freeman AF, Hagin D, Lau YL, Lionakis MS, Moreira I, Pinto JA, de Moraes-Pinto MI, Rawat A, Reda SM, Reyes SOL, Seppänen M, Tang MLK. Sullivan KE, et al. J Clin Immunol. 2017 Oct;37(7):650-692. doi: 10.1007/s10875-017-0426-2. Epub 2017 Aug 7. J Clin Immunol. 2017. PMID: 28786026 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical